vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and CSP INC (CSPI). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $12.0M, roughly 1.2× CSP INC). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs 0.8%, a 1.0% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -23.2%). CHAMPIONS ONCOLOGY, INC. produced more free cash flow last quarter ($-2.0M vs $-3.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -6.3%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
CSP Inc. is a U.S.-based technology firm offering cybersecurity solutions, managed IT services, high-performance computing systems, and IT consulting support. It serves enterprises across healthcare, finance, manufacturing, and public sectors in North America and select global markets.
CSBR vs CSPI — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $12.0M |
| Net Profit | $268.0K | $91.0K |
| Gross Margin | 51.7% | 39.3% |
| Operating Margin | 1.2% | -0.9% |
| Net Margin | 1.8% | 0.8% |
| Revenue YoY | 11.5% | -23.2% |
| Net Profit YoY | -63.2% | -80.7% |
| EPS (diluted) | $0.02 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $12.0M | ||
| Q3 25 | $14.0M | $14.5M | ||
| Q2 25 | $12.4M | $15.4M | ||
| Q1 25 | $17.0M | $13.1M | ||
| Q4 24 | $13.5M | $15.7M | ||
| Q3 24 | $14.1M | $13.0M | ||
| Q2 24 | $14.0M | $13.1M | ||
| Q1 24 | $12.0M | $13.7M |
| Q4 25 | $268.0K | $91.0K | ||
| Q3 25 | $-436.0K | $-191.0K | ||
| Q2 25 | $-1.8M | $-264.0K | ||
| Q1 25 | $4.5M | $-108.0K | ||
| Q4 24 | $728.0K | $472.0K | ||
| Q3 24 | $1.3M | $-1.7M | ||
| Q2 24 | $-109.0K | $-185.0K | ||
| Q1 24 | $-2.5M | $1.6M |
| Q4 25 | 51.7% | 39.3% | ||
| Q3 25 | 42.9% | 36.6% | ||
| Q2 25 | 41.1% | 28.8% | ||
| Q1 25 | 61.2% | 32.0% | ||
| Q4 24 | 44.9% | 29.1% | ||
| Q3 24 | 49.7% | 28.4% | ||
| Q2 24 | 48.2% | 35.0% | ||
| Q1 24 | 34.7% | 47.3% |
| Q4 25 | 1.2% | -0.9% | ||
| Q3 25 | -3.8% | -3.7% | ||
| Q2 25 | -16.2% | -7.9% | ||
| Q1 25 | 26.4% | -7.6% | ||
| Q4 24 | 5.4% | -2.3% | ||
| Q3 24 | 9.5% | -15.7% | ||
| Q2 24 | -1.9% | -5.5% | ||
| Q1 24 | -21.4% | 9.0% |
| Q4 25 | 1.8% | 0.8% | ||
| Q3 25 | -3.1% | -1.3% | ||
| Q2 25 | -14.9% | -1.7% | ||
| Q1 25 | 26.4% | -0.8% | ||
| Q4 24 | 5.4% | 3.0% | ||
| Q3 24 | 9.3% | -12.7% | ||
| Q2 24 | -0.8% | -1.4% | ||
| Q1 24 | -21.1% | 11.6% |
| Q4 25 | $0.02 | $0.01 | ||
| Q3 25 | $-0.03 | $-0.02 | ||
| Q2 25 | $-0.12 | $-0.03 | ||
| Q1 25 | $0.31 | $-0.01 | ||
| Q4 24 | $0.05 | $0.05 | ||
| Q3 24 | $0.09 | $-0.17 | ||
| Q2 24 | $-0.01 | $-0.02 | ||
| Q1 24 | $-0.19 | $0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $24.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $44.8M |
| Total Assets | $30.2M | $69.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $24.9M | ||
| Q3 25 | $10.3M | $27.4M | ||
| Q2 25 | $9.8M | $26.3M | ||
| Q1 25 | $3.2M | $29.5M | ||
| Q4 24 | $2.8M | $30.7M | ||
| Q3 24 | $2.9M | $30.6M | ||
| Q2 24 | $2.6M | $28.9M | ||
| Q1 24 | $4.5M | $27.1M |
| Q4 25 | $4.2M | $44.8M | ||
| Q3 25 | $3.5M | $44.6M | ||
| Q2 25 | $3.8M | $47.5M | ||
| Q1 25 | $5.5M | $47.5M | ||
| Q4 24 | $681.0K | $47.5M | ||
| Q3 24 | $-332.0K | $47.3M | ||
| Q2 24 | $-1.9M | $48.1M | ||
| Q1 24 | $-2.1M | $48.2M |
| Q4 25 | $30.2M | $69.2M | ||
| Q3 25 | $30.5M | $71.2M | ||
| Q2 25 | $32.3M | $66.8M | ||
| Q1 25 | $30.6M | $67.1M | ||
| Q4 24 | $25.2M | $67.5M | ||
| Q3 24 | $24.9M | $69.4M | ||
| Q2 24 | $26.1M | $66.8M | ||
| Q1 24 | $26.8M | $64.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-2.9M |
| Free Cash FlowOCF − Capex | $-2.0M | $-3.0M |
| FCF MarginFCF / Revenue | -13.1% | -25.1% |
| Capex IntensityCapex / Revenue | 1.6% | 0.9% |
| Cash ConversionOCF / Net Profit | -6.47× | -32.04× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-2.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-2.9M | ||
| Q3 25 | $600.0K | $1.9M | ||
| Q2 25 | $6.9M | $-3.3M | ||
| Q1 25 | $490.0K | $1.9M | ||
| Q4 24 | $-283.0K | $1.7M | ||
| Q3 24 | $311.0K | $-1.5M | ||
| Q2 24 | $-1.8M | $2.4M | ||
| Q1 24 | $-919.0K | $1.7M |
| Q4 25 | $-2.0M | $-3.0M | ||
| Q3 25 | $554.0K | $1.7M | ||
| Q2 25 | $6.6M | $-3.3M | ||
| Q1 25 | $448.0K | $1.9M | ||
| Q4 24 | $-377.0K | $1.7M | ||
| Q3 24 | — | $-1.5M | ||
| Q2 24 | $-1.8M | $2.4M | ||
| Q1 24 | $-1.0M | $1.6M |
| Q4 25 | -13.1% | -25.1% | ||
| Q3 25 | 4.0% | 11.5% | ||
| Q2 25 | 53.5% | -21.7% | ||
| Q1 25 | 2.6% | 14.5% | ||
| Q4 24 | -2.8% | 10.8% | ||
| Q3 24 | — | -11.7% | ||
| Q2 24 | -13.0% | 17.9% | ||
| Q1 24 | -8.4% | 11.9% |
| Q4 25 | 1.6% | 0.9% | ||
| Q3 25 | 0.3% | 1.6% | ||
| Q2 25 | 2.0% | 0.4% | ||
| Q1 25 | 0.2% | 0.1% | ||
| Q4 24 | 0.7% | 0.3% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 0.8% | 0.1% |
| Q4 25 | -6.47× | -32.04× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | 3.69× | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
CSPI
| Products | $6.7M | 56% |
| Services | $5.3M | 44% |
